Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
WINT logo WINT
Upturn stock ratingUpturn stock rating
WINT logo

Windtree Therapeutics Inc (WINT)

Upturn stock ratingUpturn stock rating
$0.52
Last Close (24-hour delay)
Profit since last BUY-56.3%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: WINT (1-star) is a SELL. SELL since 1 days. Profits (-56.30%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $0.36
Current$0.52
52w High $662

Analysis of Past Performance

Type Stock
Historic Profit -90.19%
Avg. Invested days 12
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.15M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 1
Beta 0.63
52 Weeks Range 0.36 - 662.00
Updated Date 08/15/2025
52 Weeks Range 0.36 - 662.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -6321.5

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -53.2%
Return on Equity (TTM) -124.86%

Valuation

Trailing PE -
Forward PE 0.37
Enterprise Value 6557844
Price to Sales(TTM) 660.53
Enterprise Value 6557844
Price to Sales(TTM) 660.53
Enterprise Value to Revenue 706.08
Enterprise Value to EBITDA 0.01
Shares Outstanding 11908300
Shares Floating 3661289
Shares Outstanding 11908300
Shares Floating 3661289
Percent Insiders -
Percent Institutions 0.18

ai summary icon Upturn AI SWOT

Windtree Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Windtree Therapeutics, Inc. was founded in 1992. Initially focused on surfactant therapies for respiratory distress syndrome (RDS) in premature infants, the company has evolved to focus on developing novel therapies for acute respiratory conditions.

business area logo Core Business Areas

  • Aerosurf: Aerosurf is a novel, investigational combination drug/device product that delivers aerosolized KL4 surfactant to premature infants with respiratory distress syndrome (RDS) without intubation.
  • ISTR: ISTR is focused on developing products addressing acute pulmonary conditions. Windtree is developing AEROSURF for use in neonates with respiratory distress syndrome (RDS), as well as rostafuroxin for cardiogenic shock.

leadership logo Leadership and Structure

Craig Fraser is the President & CEO. The organizational structure consists of functional departments such as research and development, clinical operations, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Aerosurf: Aerosurf is an investigational drug/device combination for RDS in premature infants. Since the product is not yet approved, there is no current market share. Competitors in the RDS market include Mallinckrodt (INOpulse), and various forms of traditional surfactant administration.
  • Rostafuroxin: Rostafuroxin is a novel treatment for cardiogenic shock. Since the product is not yet approved, there is no current market share. Competitors include existing inotropic agents.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is intensely competitive and fragmented. The market for acute respiratory therapies is driven by unmet medical needs and technological advancements.

Positioning

Windtree Therapeutics is positioned as a specialty pharmaceutical company focused on innovative therapies for respiratory conditions. Their competitive advantage lies in their novel surfactant technology and targeted therapeutic approach.

Total Addressable Market (TAM)

The TAM for RDS and cardiogenic shock is significant, estimated to be in the billions of dollars. Windtree aims to capture a portion of this market with its innovative products, but the precise TAM is dependent on approval and adoption rates.

Upturn SWOT Analysis

Strengths

  • Novel surfactant technology (KL4)
  • Potential for non-invasive treatment of RDS
  • Experienced leadership team
  • Focus on unmet medical needs

Weaknesses

  • Reliance on successful clinical trials
  • Limited financial resources
  • Dependence on regulatory approval
  • Small market capitalization

Opportunities

  • Expanding indications for surfactant technology
  • Partnerships with larger pharmaceutical companies
  • Orphan drug designation benefits
  • Advancements in drug delivery systems

Threats

  • Clinical trial failures
  • Competition from established therapies
  • Regulatory hurdles
  • Economic downturns impacting funding

Competitors and Market Share

competitor logo Key Competitors

  • MNK (Mallinckrodt)
  • RDHL (Redhill Biopharma Ltd.)
  • INSYS

Competitive Landscape

Windtree faces intense competition from established pharmaceutical companies with approved therapies. Their advantage lies in their innovative technology, but they must overcome significant regulatory and commercial hurdles.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the lack of approved products. The company's growth is tied to the successful development and commercialization of its pipeline.

Future Projections: Future growth depends on clinical trial outcomes and regulatory approvals. Analyst projections are highly variable and dependent on these factors.

Recent Initiatives: Recent initiatives include advancing Aerosurf clinical trials, seeking regulatory approvals, and exploring potential partnerships.

Summary

Windtree Therapeutics is a development-stage pharmaceutical company with innovative technology targeting respiratory conditions. While its novel surfactant technology holds promise, the company faces challenges related to clinical trial success, regulatory approval, and securing funding. The lack of approved products makes it a higher-risk investment, and it must capitalize on partnership opportunities.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Windtree Therapeutics Investor Relations
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Windtree Therapeutics Inc

Exchange NASDAQ
Headquaters Warrington, PA, United States
IPO Launch date 1995-08-08
CEO, President & Director Mr. Jed A. Latkin
Sector Healthcare
Industry Biotechnology
Full time employees 14
Full time employees 14

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.